At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 97 enrolled
Drug / intervention
Tociliuzumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia
In Brief
A Phase 2 clinical trial evaluating Tociliuzumab for COVID-19 Pneumonia. Completed, enrolled 97 participants across 24 sites.
Detailed Summary
This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in hospitalized adult participants with moderate to severe COVID-19 pneumonia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Pneumonia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartMay 2020
Primary CompletionAug 2020
TodayJul 2026
First PostedApr 27, 2020
Enrollment StartMay 5, 2020
Primary CompletionAug 12, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.2 years ago
Interventions
Tociliuzumabdrug
Participants will receive IV TCZ.